Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ABBV-368 (Revdofilimab) in Advanced Solid Tumors
NCT03071757Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2017
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of revdofilimab in solid tumor, triple-negative breast cancer (TNBC) and head and neck squamous cell carcinoma (HNSCC) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Terminal half-life at 2 years, Area under the serum concentration-time curve at 2 years and 6 more. Started Mar 2017; status: completed.
02
Drugs
revdofilimab
03
Conditions
solid tumortriple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03071757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071757.